Developing a New Specialty Multidisciplinary Clinic While Orienting as a Novice Nurse Navigator

October 2016 Vol 7, No 9
Jeanne Kenna, RN, OCN, CRNI
Lehigh Valley Health Network
Allentown, PA
Angela Miller, RN, BSN, OCN, MEd
Lehigh Valley Health Network
Allentown, PA
Alyssa Pauls, RN, BSN, OCN
Lehigh Valley Health Network
Allentown, PA
Raizalie Roman, RN, BSN, OCN
Lehigh Valley Health Network,
Allentown, PA
Kathleen Sevedge, RN, MA, AOCN
Lehigh Valley Health Network
Allentown, PA
Cynthia Smith, RN, BSN, OCN, MA
Lehigh Valley Health Network
Allentown, PA
Laura Beaupre, RN, BSN, OCN, CN-BN
Lehigh Valley Health Network
Allentown, PA
Maritza Chicas, RN, BSN, OCN
Lehigh Valley Health Network
Allentown, PA

Background: As our cancer program evolves with multidisciplinary care, leadership approved adding 2 specialty multidisciplinary clinics (MDCs), hepatobiliary (GI) and skin and soft tissue (SST) to existing breast, thoracic, and prostate MDCs. Physicians were invested in developing these MDCs. Our model of MDC coordination by nurse navigators required hiring 2 navigators facing the chal_lenges of learning the role as well as developing the clinics.

Objectives: Identify

Background: As our cancer program evolves with multidisciplinary care, leadership approved adding 2 specialty multidisciplinary clinics (MDCs), hepatobiliary (GI) and skin and soft tissue (SST) to existing breast, thoracic, and prostate MDCs. Physicians were invested in developing these MDCs. Our model of MDC coordination by nurse navigators required hiring 2 navigators facing the chal­lenges of learning the role as well as developing the clinics.

Objectives: Identify “must haves” to develop an MDC; demonstrate high patient satisfaction; establish and nurture relationship with physician team; improve novice navigators’ competency through structured orientation.

Methods: Guided by NCCCP MDC Assessment Tool and Oncology Roundtable “Maximizing the Value of Patient Navigation,” navigator interviews involved physicians, key to assuring the right fit. MDC “must haves” were identified by physicians completing an LVHN MDC application form. “Must haves” in place included physician team, support staff, and clinic space. Metrics chosen were patient satisfaction (homegrown tool) and volumes. Patient satisfaction should match existing MDCs. Navigators completed an 8-week orientation with a competency checklist and preceptor that included shadowing navigators, attending specialty MDCs, and meeting with cancer support staff to understand their roles. Shadowing physicians and observing surgeries were crucial in establishing collegial relations. Navigators self-educated and researched their specialty through NCCN guidelines, the LVHN standard. Navigators attended MDC team meetings to plan the start-up of their MDC.

Results: An 8-week orientation competency checklist was completed. Navigator/physician relationship began with interviews and continued through orientation. Overall patient satisfaction score for SST = 4.7/5, for GI = 4.9/5. Existing goal is 4.7/5. Anticipated MDC volumes for SST = 50/year; GI = 144/year; actual to date for SST at 6 months = 29, GI at 7 months = 37.

Conclusions: The navigator as coordinator of the MDC has proven successful and yielded high patient satisfaction. Administrative and physician support for both the MDC and the investment in a structured, comprehensive navigator orientation were critical to the success of a new MDC. As the navigator assumes the role of coordinator, development of collegial relationships among all team members is also critical. MDCs are marks of quality and can differentiate your program from the competition.

Related Articles
Assessment of Side Effects (SEs) Impacting Quality of Life (QOL) in Patients (Pts) Undergoing Treatment (tx) for Advanced Breast Cancer (ABC) in Clinical Practice: A Real-World (RW) Multicountry Survey
November 2022 Vol 13, No 11
To examine how SEs impacting QOL in pts with ABC are perceived.
Intracranial Activity of Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non–Small-Cell Lung Cancer (NSCLC) Enrolled in VISION
November 2022 Vol 13, No 11
To provide analysis of the intracranial activity of tepotinib in patients with METex14 skipping NSCLC with BM from the VISION study to aid oncology nurse navigators who manage this population of patients.
MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor
November 2022 Vol 13, No 11
MF is a rare bone marrow cancer characterized by fibrosis, abnormal blood cell production, and dysregulated JAK/STAT signaling.1,2
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country